Fig. 1: Conventional biomarker analysis vs. patient-specific signaling signature analysis. | npj Precision Oncology

Fig. 1: Conventional biomarker analysis vs. patient-specific signaling signature analysis.

From: Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations

Fig. 1

Genetic/protein biomarker analysis relies on the evaluation of the expression levels of common cancer-type-associated genes or proteins (left). The design of a drug combination is done according to an inference of the state of the surrounding signaling network, based on previous knowledge (left). In contrast, patient-specific signaling signature (PaSSS) analysis involves proteomic analysis of hundreds of cancer-associated proteins, and unbiased identification of the altered signaling signature in every sample, i.e., that does not depend on previous knowledge of melanoma-related signaling pathways. This enables rationally designing personalized combinations of targeted drugs that are based on the patient-specific uniquely rewired signaling network (right).

Back to article page